{"prompt": "['Novartis', 'Confidential', 'Page 33', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'be performed by monitors during site visits or remotely and at the completion of the trial.', 'Patients will be asked to return all unused non- investigational treatment and packaging at the', 'end of the run-in for the run-in medication and at the end of the study or at the time of', 'discontinuation of investigational treatment for the rescue medication.', 'These medications are:', 'Salbutamol (100 g) or albuterol (90 g) used as rescue medication', 'Salmeterol xinafoate/fluticasone propionate 50/250 g b.i.d. or 50/500 g b.i.d. via', 'AccuhalerR used as run-in medication', 'Details are described in the CRF completion guidelines.', '5.5.4 Instructions for prescribing and taking study treatment', 'At Visit 1 all patients will be instructed on how to use a Metered Device Inhaler (MDI) to', 'administer rescue medication, salbutamol. Patients will be instructed to take rescue', 'medication on an \"as needed\" basis throughout the study. In order to standardize', 'measurements, patients will be instructed to abstain from taking rescue medication within 6', 'hours of the start of each visit unless absolutely necessary.', 'At Visit 101 patients will be trained on how to properly use open-label run-in medication', 'salmeterol/fluticasone via AccuhalerR and will be instructed to take b.i.d. per instructions in', 'Appendix 4.', 'At Visit 201 patients will be trained on how to properly use the Conceptl inhaler device or the', 'Accuhaler plus Respimat\u00ae inhaler devices based on the randomized treatment arm provided', 'by IRT. Patients who are unable to use the assigned device(s) correctly at Visit 201 will not', \"continue in the study. At clinic visits the investigator should check the patient's use of the\", 'inhalational devices to ensure that they are using each device correctly. Additional device', 'training should be provided as required.', 'QVM149 Treatment arms once daily evening dose:', 'Patients will be instructed to inhale 1 QVM149 capsule using the provided Conceptl device', '(pack bearing only a moon < pictogram) in the evening between 5:00 and 8:00 pm. QVM149', 'study treatment must only be taken once a day in the evening. The first dose will be', 'administered in the clinic at Visit 201.', 'Open label salmeterol /fluticasone twice daily + tiotropium once daily evening dose:', 'Patients will be instructed to take:', 'MORNING between 5:00 and 8:00 am: 1 inhalation from the Accuhaler device', 'containing salmeterol/fluticasone (package bearing both a sun', 'and', 'moon', '<', 'pictogram)', 'EVENING between 5:00 and 8:00 pm: 1 inhalation from the Accuhaler device', 'containing salmeterol/fluticasone (package bearing both a sun', 'and moon', '<', 'pictogram)', 'followed directly by 2 inhalations from the Respimat\u00ae device containing tiotropium', '(package bearing only a moon < pictogram). Tiotropium via Respimat\u00ae must only be', 'taken once a day in the evening. The first dose will be administered in the clinic at Visit', '201.']['Novartis', 'Confidential', 'Page 34', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Table 5-1', 'Study Treatments', 'Treatment arm', 'Morning', 'Evening <', 'QVM149 150/50/80 g', 'No dose', '1 capsule via Conceptl', 'or', 'QVM149 150/50/160 g', 'Salmeterol xinafoate/fluticasone', '1 inhalation via', '1 inhalation via Accuhaler8', 'propionate 50/500 g', 'Accuhaler', '+', '+', '2 inhalations via Respimat', 'Tiotropium 5 g o.d', 'Patients will be instructed to rinse their mouth after inhalation of study drug (2 times with', 'approximately 30 mL water). Water used for mouth rinsing should be spat out and should', 'NOT be swallowed. When sequential inhalations of study drugs from two devices are', 'required, mouth rinsing should be done after the last inhalation. Patients will also be', 'instructed to take medication at approximately the same designated time while at home in', 'between visits.', 'Instructions for use of the Conceptl, Accuhaler\u00ae, and Respimat\u00ae devices are given in', 'Appendix 3, Appendix 4, and Appendix 5.', 'The study treatment can be taken without regard to sleep, meals, and other activities. On days', 'of scheduled clinic visits, patients should take their evening dose of study treatment at the', 'clinic.', 'The duration of active treatment is 24 weeks, with the last dose of study treatment occurring', 'at Visit 204.', 'All kits of investigational treatment assigned by the IRT will be recorded in the IRT. All used', 'and unused study medication/packaging (except used capsules) must be returned by the', 'patient at each study visit and/or at the time of discontinuation.', 'The investigator should promote compliance by instructing the patient to take the study', \"treatment exactly as prescribed and by stating that compliance is necessary for the patient's\", 'safety and the validity of the study. The patient should be instructed to contact the investigator', 'if he/she is unable for any reason to take the study treatment as prescribed.', 'If any faults are identified with either the device and/or the blisters, these should be returned', 'to Novartis Drug Supply Management with the completed Device Return Form. The forms', 'will be supplied to each investigator site by the Field Monitor.', '5.5.5 Permitted dose adjustments and interruptions of study treatment', 'Investigational treatment dose adjustments and/or interruptions are not permitted unless the', 'investigator considers an interruption is necessary for the treatment of an adverse event. Any', 'interruption of study medication should be for the shortest time period possible. Every', 'interruption due to an adverse event must be recorded in the Dosage Administration Record', 'CRF (e-CRF). Interruptions of more than 5 days for other reasons must also be recorded in', 'the Dosage Administration Record CRF (e-CRF).']\n\n###\n\n", "completion": "END"}